2024-03-28T14:48:33Zhttp://digital.csic.es/dspace-oai/requestoai:digital.csic.es:10261/596112021-06-07T10:56:54Zcom_10261_54com_10261_1col_10261_307
Poirier, R.
Fernández García, Ana María
Torres Alemán, Ignacio
Metzger, F.
2012-11-06T15:51:20Z
2012-11-06T15:51:20Z
2012
Neuroscience Letters 509: 101- 104 (2012)
http://hdl.handle.net/10261/59611
10.1016/j.neulet.2011.12.048
The influence of insulin-like growth factor I (IGF-I) on the progression of Alzheimer's disease (AD) is discussed controversially. To help clarify the role of this circulating neurotrophic factor in brain amyloidosis, the major pathological trait in AD, we analyzed plaque formation in a mouse model of AD transgenic for human APP and PS1 mutations with reduced serum IGF-I levels (LIDAD mice). We found that brain amyloidosis in LIDAD mice appeared earlier than in AD mice, at 2 months of age, while attained comparable levels at 6 months. In parallel, early microgliosis was observed in LIDAD mice also at 2 months and remained exacerbated at 6 months. Collectively, these observations suggest a role of serum IGF-I in delaying early brain amyloidosis. © 2012 Elsevier Ireland Ltd.
eng
closedAccess
Early brain amyloidosis in APP/PS1 mice with serum insulin-like growth factor-I deficiency
artículo